Cargando…

S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome

 : S9.4 Free oral presentations (late breaking), September 23, 2022, 4:45 PM - 6:15 PM PURPOSE: To report antifungal susceptibility and clinical correlations in melanized fungal isolates of Curvularia lunata and Lasiodiplodia theobromae from ocular infections. METHODS: Antifungal susceptibility test...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitra, Sanchita, Garg, Prashant, Murthy, Somasheila, Dave, Vivek Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511641/
http://dx.doi.org/10.1093/mmy/myac072.S9.4a
_version_ 1784797682489884672
author Mitra, Sanchita
Garg, Prashant
Murthy, Somasheila
Dave, Vivek Pravin
author_facet Mitra, Sanchita
Garg, Prashant
Murthy, Somasheila
Dave, Vivek Pravin
author_sort Mitra, Sanchita
collection PubMed
description  : S9.4 Free oral presentations (late breaking), September 23, 2022, 4:45 PM - 6:15 PM PURPOSE: To report antifungal susceptibility and clinical correlations in melanized fungal isolates of Curvularia lunata and Lasiodiplodia theobromae from ocular infections. METHODS: Antifungal susceptibility testing was performed by broth microdilution testing, following Clinical and Laboratory Standard Institute guidelines, of 17 C. lunata and 13 L. theobromae isolates from monomicrobial infections of microbial keratitis or fungal endophthalmitis patients. Isolates resistant to ≥2 classes of antifungals were considered as multidrug-resistant (MDR). The panel of antifungals tested were amphotericin B, natamycin, voriconazole, ketoconazole, fluconazole, itraconazole, posaconazole, and caspofungin. RESULTS: Voriconazole showed the highest susceptibility (83.3% isolates) followed by natamycin (80%), fluconazole (80%), itraconazole (76.7%), ketoconazole (70%), posaconazole, and caspofungin (66.7% each) and lastly amphotericin B (63.3%). For treatment, all patients received topical natamycin, and few received additional oral ketoconazole or intraocular voriconazole. MDR isolates led to the poorer clinical outcomes (P=.015) in patients. But natamycin resistance alone did not show unfavorable outcomes (P=.28), though this was the most frequent drug used topically in fungal ocular infections. CONCLUSION: Melanized fungi causing ocular infections have varying susceptibility to different antifungal agents. Most effective drug as seen in vitro in our study, was voriconazole. Significant resistance to amphotericin B, which is the most common antifungal used in intravitreal injections, was noted. MDR isolates overall, had poorer clinical outcomes.
format Online
Article
Text
id pubmed-9511641
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95116412022-09-27 S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome Mitra, Sanchita Garg, Prashant Murthy, Somasheila Dave, Vivek Pravin Med Mycol Oral Presentations  : S9.4 Free oral presentations (late breaking), September 23, 2022, 4:45 PM - 6:15 PM PURPOSE: To report antifungal susceptibility and clinical correlations in melanized fungal isolates of Curvularia lunata and Lasiodiplodia theobromae from ocular infections. METHODS: Antifungal susceptibility testing was performed by broth microdilution testing, following Clinical and Laboratory Standard Institute guidelines, of 17 C. lunata and 13 L. theobromae isolates from monomicrobial infections of microbial keratitis or fungal endophthalmitis patients. Isolates resistant to ≥2 classes of antifungals were considered as multidrug-resistant (MDR). The panel of antifungals tested were amphotericin B, natamycin, voriconazole, ketoconazole, fluconazole, itraconazole, posaconazole, and caspofungin. RESULTS: Voriconazole showed the highest susceptibility (83.3% isolates) followed by natamycin (80%), fluconazole (80%), itraconazole (76.7%), ketoconazole (70%), posaconazole, and caspofungin (66.7% each) and lastly amphotericin B (63.3%). For treatment, all patients received topical natamycin, and few received additional oral ketoconazole or intraocular voriconazole. MDR isolates led to the poorer clinical outcomes (P=.015) in patients. But natamycin resistance alone did not show unfavorable outcomes (P=.28), though this was the most frequent drug used topically in fungal ocular infections. CONCLUSION: Melanized fungi causing ocular infections have varying susceptibility to different antifungal agents. Most effective drug as seen in vitro in our study, was voriconazole. Significant resistance to amphotericin B, which is the most common antifungal used in intravitreal injections, was noted. MDR isolates overall, had poorer clinical outcomes. Oxford University Press 2022-09-20 /pmc/articles/PMC9511641/ http://dx.doi.org/10.1093/mmy/myac072.S9.4a Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Mitra, Sanchita
Garg, Prashant
Murthy, Somasheila
Dave, Vivek Pravin
S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title_full S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title_fullStr S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title_full_unstemmed S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title_short S9.4a Ocular infections by melanized fungi Curvularia lunata and Lasiodiplodia theobromae: Antifungal susceptibility and clinical outcome
title_sort s9.4a ocular infections by melanized fungi curvularia lunata and lasiodiplodia theobromae: antifungal susceptibility and clinical outcome
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511641/
http://dx.doi.org/10.1093/mmy/myac072.S9.4a
work_keys_str_mv AT mitrasanchita s94aocularinfectionsbymelanizedfungicurvularialunataandlasiodiplodiatheobromaeantifungalsusceptibilityandclinicaloutcome
AT gargprashant s94aocularinfectionsbymelanizedfungicurvularialunataandlasiodiplodiatheobromaeantifungalsusceptibilityandclinicaloutcome
AT murthysomasheila s94aocularinfectionsbymelanizedfungicurvularialunataandlasiodiplodiatheobromaeantifungalsusceptibilityandclinicaloutcome
AT davevivekpravin s94aocularinfectionsbymelanizedfungicurvularialunataandlasiodiplodiatheobromaeantifungalsusceptibilityandclinicaloutcome